ZTSZoetis Inc.
Zoetis Inc. sells veterinary medicines and vaccines for companion animals and livestock, with a focus on high-margin products in the U.S. and international markets. The next catalyst is Oct 15, 2026 — Companion Animal Pipeline & R&D Strategy Update, which will test the company’s ability to sustain growth in its core markets and defend its R&D pipeline against generic competition.
- Zoetis operates in a niche but high-margin segment of the pharmaceutical industry, with a strong presence in companion animal health.
- The company has a debt-to-equity ratio of 2.71x, suggesting a leveraged balance sheet that could amplify returns or risks.
- Free cash flow of $3.47B in the trailing twelve months reflects strong cash generation, but the company’s net margin of 28.5% is below industry peers.
The Read
Zoetis's stock rose about 2.1% on a Q4 2025 earnings beat and strong 2026 guidance driven by international and companion animal demand, then showed muted reactions to Q1 2026 results and industry updates amid lawsuit noise, before falling about 7.3% due to securities litigation concerns.
The schedule
- Thu15Oct
Strategic R&D update focusing on next-generation companion animal therapeutics and pipeline visibility.
- Fri15Jan
Evaluation of impending generic and biosimilar competition affecting legacy product lines.
- Sun31Jan
Third-quarter earnings, focusing on volume stabilization in the U.S. veterinary market.
- Tue9Feb
Fourth-quarter results and the critical release of initial full-year 2027 financial guidance.
- Thu6May
First-quarter earnings release and evaluation of early 2027 operational execution.
- Thu5Aug
Past
- Tue4Aug
Actual outcome: Bear · $51.86 at outcome
Stock fell 17.2% from event to outcome date, aligning with the bear trajectory.
Zoetis reports its Q2 results following a severe drawdown that compressed its valuation to 12.8x P/E amidst class-action litigation overhangs.
- Mon20Jul
Actual outcome: Bear · $74.19 at outcome
Price reached or fell below bear floor ($74.00) at outcome date.
- Thu28May
Actual outcome: Mixed · $77.69 at outcome
The stock experienced a muted reaction, falling just 0.7% to close at $77.69, remaining well between the bull and bear targets. While Zoetis presented at the Stifel Jaws & Paws Conference to discuss industry trends, the news cycle was heavily dominated by a barrage of securities fraud class action lawsuit announcements, leading to flat and ambiguous price action without a clear directional catalyst.
- Thu7May
Actual outcome: Bear · $82.83 at outcome
Zoetis reported Q1 EPS of $1.42, exactly matching analyst estimates. Despite meeting bottom-line expectations, the stock fell 5.1% and broke well below the bear floor, indicating that investors were disappointed by other elements of the report such as forward guidance or underlying segment performance.
- Thu12Feb
Actual outcome: Bull · $125.56 at outcome
Zoetis delivered a clear beat on Q4 2025 earnings ($1.48 vs. $1.40 estimate) and revenue estimates. Crucially, the company issued strong full-year 2026 guidance for both profit and revenue that exceeded consensus estimates, driven by resilient international markets and steady companion animal demand. This strong forward outlook, which addressed market focus on growth acceleration, propelled the stock past the bull target of $128.00.
